You are reading this latest preprint version Therapeutic vaccines for non-small cell lung cancer (NSCLC) are almost invariably designed against global HLA supertypes, yet the immunogenetics of Southeast Asian patients diverges substantially from the largely European allele sets underlying them....
Research ArticleArticles in Press109560August 07, 2026Open accessClinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world studyLaura Masfarra ∙ Ana Sofia De Freitas Matos Parreirab ∙ Natalia Castroc ∙ … ∙ Claudia Miquela ∙ Nil...
Benjamin Herzberg, MD In an interview with Targeted OncologyTM, Benjamin Herzberg, MD, of the Division of Hematology/Oncology at Columbia University Irving Medical Center, outlined the most pressing unmet needs in KRAS-mutant non–small cell lung cancer (NSCLC), discussed how he sequences...
GFH375 becomes first oral KRAS G12D inhibitor entering Phase III trials for NSCLC. GenFleet Therapeutics' Kylin-Flight 01 study shows promising progress China-based GenFleet Therapeutics (Shanghai) Inc. (HKEX: 02595) announced on August 10 that the first patient has been dosed in...
Treatment of NSCLC KRAS G12C mutant tumors with the allele-selective sotorasib and adagrasib inhibitors is invariably associated with acquired resistance. The MUC1-encoded oncogenic M1C protein is necessary for self-renewal of NSCLC KRAS mutant cells. We report that treatment of NSCLC...
The FDA has granted breakthrough therapy designation to olomorasib (LY3537982) as a monotherapy for adult patients with advanced pancreatic cancer harboring a KRAS G12C mutation who have received at least 1 prior systemic therapy, according to a news release from...
Silexion Therapeutics Corp. (NASDAQ: SLXN) announced new preclinical findings showing that its drug candidate SIL204 produced statistically significant changes in immune-related gene expression across human KRAS-mutant cancer... Silexion Therapeutics Corp. (NASDAQ: SLXN) announced new preclinical findings showing that its drug...
AbstractBackground KRAS‑mutant non‑small cell lung cancer (NSCLC) is heterogeneous, but the subtype‑specific profiles of systemic cytokines and their impact on immunotherapy outcomes remain unclear. Methods This retrospective study included 139 patients with KRAS‑mutant NSCLC stratified into G12C (44.6%), G12D (21.6%),...
Abstract Non-small cell lung cancer (NSCLC) with KRASG12C mutation is associated with poor prognosis and resistance to standard therapies. Sotorasib, a KRASG12C tyrosine kinase inhibitor, has shown clinical efficacy, yet its interaction with different irradiation modalities remains unclear. This study...
AbstractBackground To establish a historical benchmark by describing the treatment patterns and clinical outcomes of Chinese patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) in the real world, prior to the widespread availability of KRAS G12C inhibitors. Methods...
